Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis - Full Text View - ClinicalTrials...
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis. Cat-PAD is a novel synthetic, allergen derived peptide desensitizing vaccine currently being developed for the treatment of cat allergy.. At present, the efficacy of immunotherapy (peptide or otherwise) can only be established at the conclusion of therapy. The aim of this study is to identify changes in potential biomarkers after peptide immunotherapy that may be subsequently developed as biomarkers that equate with clinical efficacy. ...https://clinicaltrials.gov/ct2/show/NCT01383590
British Library EThOS: Dosing strategy for effective peptide immunotherapy of experimental autoimmune disease
Previous work has shown that repetitive intranasal (i.n.) administration of the myelin basic protein peptide MBP Acl-9[4Y] induces tolerance in the TCR transgenic Tg4 EAE model. Chronic antigen stimulation of C04+ T cells was found to induce an anergic IL-l0-secreting regulatory phenotype in Th-I cells, protecting animals from EAE. Alternative routes for peptide administration were explored in the Tg4 model, to increase our understanding of the factors influencing peptide immunotherapy. Epicutaneously (e. c.) administered MBP Acl- 9[4Y] was slowly trafficked to the lymph nodes and spleen where C04+ T cells were activated. However, repetitive e.c. MBP Acl-9[4Y] administration did not reliably induce characteristics of C04+ T cell tolerance, attributed to the difficulty of controlling the e.c. administered MBP Acl-9 [4 Y] dose. Use of the subcutaneous (s.c.) route circumvented this problem, and titrated MBP Acl-9[4Y] doses were administered s.c. to Tg4 mice. Tolerance induced was proportional ...http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.560490
RXi to Acquire Peptide Immunotherapy Firm Apthera | GenomeWeb
The deal gives RXi a late-stage peptide immunotherapy for breast cancer and marks a shift in strategy that nudges the company from its previous focus as a pure-play RNAi shop.https://www.genomeweb.com/rnai/rxi-acquire-peptide-immunotherapy-firm-apthera
Novel immunotherapeutic Combination Clinical Trials
However, many patients are primarily resistant to immune checkpoint blockade -based monotherapy and many others will eventually relapse. As we start utilizing more of immunotherapeutic agents as standard of care and part of clinical trials, we need to think about potential resistance and developing novel combinations. Besides the B7 co-inhibitory receptors, OX40 (CD134), 4-1 BB (CD137) are co-stimulatory molecule can be expressed by activated immune cells and trials are ongoing with drugs targeting these alone or in combination with checkpoint inhibitors. In addition, there are novel intratumoral agents like TLR7/8 agonists, which are being tested in trials ...http://www.icto2017.com/novel-immunotherapeutic-combination-clinical-tria.aspx
Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses | JEM
Recent clinical outcomes and subsequent approvals of anti-CTLA-4 and anti-PD-1 checkpoint blockade antibodies, which mitigate inhibitory signaling that decreases antitumor T cell responses, have ignited extraordinarily broad efforts to develop the potential of cancer immunotherapy (Pardoll, 2012; Topalian et al., 2015). Unlike strategies that typically elicit antitumor responses of limited duration and nearly inevitable treatment resistance, immunotherapeutics can achieve durable and long-lasting antitumor responses in a minority of patients with advanced disease (Sharma and Allison, 2015). To build upon this success, combination immunotherapies are a next logical step (Gajewski et al., 2013; Spranger and Gajewski, 2013).. One such approach combines a tumor-specific antibody to drive antibody-dependent cell-mediated cytotoxicity (ADCC) through neutrophil- and eosinophil-mediated attack and an extended serum half-life IL-2 fusion to activate CD8+ T cells and NK cells. However, this strategy ...http://jem.rupress.org/content/early/2017/05/03/jem.20160831
Kidney Disease Treatment www.kidney-support.org: Immunotherapy on Treating Kidney Disease
As we know, Immunotherapy have the proficiency of multiple-differentiation and "infinite proliferation", and Immunotherapy have the characteristics of immune regulation and self-replication. Therefore, it can be used as "seed cells " to repair the impairment or injuries of various tissues and organs. And in recent years, it has been discovered that Immunotherapy can differentiate into renal intrinsic cells and renal essence cells, so Immunotherapy have the function of repair and rebuild for the damaged kidneys. What's more, Immunotherapy have the same effective mechanism of micro-chinese medicine osmotherapy, so the two therapies have the function of supplement each other ...http://kidneytreatmentcn.blogspot.com/2016/04/immunotherapy-on-treating-kidney-disease.html
Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD). - Full Text View - ClinicalTrials.gov
Pilot and open RCT in 20 patients with primary HIV-1 infection who were randomized to one of these two arms: 1) Control arm (A), Tenofovir +Lamivudine + Lopinavir-ritonavir (Kaletra) at standard doses for 44 weeks (W44); a short treatment interruption (TI) was performed at W36, and HAART was restarted for 8 weeks when plasma HIV-1 RNA viral load (pVL) rebounded,200 copies/mL. At W44 HAART was stopped and patients were followed for 48 additional weeks (W92). 2) Immune-based arm (B), same HAART schedule plus oral cyclosporine A (CsA)(serum levels 250-350 mcg/L) for the first 8 weeks of HAART. During the TI, patients received sc GM-CSF (250 mcg TIW) plus weekly sc pegylated-interferon a2b (Peg-INF)(1.5 mcg/kg/week). During the last 8 weeks of HAART (until W44), patients received daily sc low-dose interleukin-2 (IL-2)(0.75 MU/kg QD). The primary endpoint was pVL ,1000copies/mL (,3.0 log10/mL) at 12 (W56) and at 48 (W92) weeks after stopping HAART. Sample size was calculated in order to detect a pVL ...https://clinicaltrials.gov/show/NCT00979706?order=260
Cancer Immunotherapy Market Sales Segmentation with Manufacturers, Types, Application and Growth Analysis by Regions from 2016...
Get Sample PDF of Cancer Immunotherapy Market Report@ http://www.360marketupdates.com/enquiry/request-sample/10316977. After the basic information, the report sheds light on the production. Production plants, their capacities, global production and revenue are studied. Also, the Cancer Immunotherapy market growth in various regions and R&D status are also covered.. Further in the report, the global Cancer Immunotherapy market is examined for price, cost and gross. These three points are analysed for types, companies and regions. In continuation with this data sale price is for various types, applications and region is also included.. The global Cancer Immunotherapy market consumption for major regions is given. Additionally, type wise and application wise consumption figures are also given.. Ask for Discount@ http://www.360marketupdates.com/enquiry/request-discount/10316977. Split by product Types, with sales, revenue, price and gross ...http://www.abnewswire.com/pressreleases/cancer-immunotherapy-market-sales-segmentation-with-manufacturers-types-application-and-growth-analysis-by-regions-from-2016-to-2021_83165.html
Advances in Combination Tumor Immunotherapy | Frontiers Research Topic
Recent clinical studies have highlighted the therapeutic efficacy of cancer immunotherapy, such as T cell immune checkpoint blockade with anti-CTLA-4 or anti-PD-1 mAb. In metastatic melanoma, these agents have shown an unprecedented capacity to induce durable object responses lasting for many years; however, the percentage of patients experiencing such profound clinical benefit remains small. Having established this unique capacity of immunotherapy to mediate such durable melanoma tumor rejections, the focus of the field has shifted toward increasing the percentage of cancer patients who benefit from this therapy. The combination of CTLA-4 and PD-1 antibodies synergized in rejecting tumors in a mouse melanoma model, and produced a remarkable 53% objective response rate in a Phase I trial of metastatic melanoma patients. This trial demonstrated the feasibility and potential therapeutic efficacy of combination immunotherapy for the treatment of patients with ...https://www.frontiersin.org/research-topics/2886/advances-in-combination-tumor-immunotherapy
World Immunotherapy Congress USA 2017 - ADC Review ADC Review
Discover. Develop. Get to market. For Biotech, Pharma, and Their Partners.. The demand for innovation in immunotherapy can only grow, and new breakthroughs are needed if success rates are to continue. That's why World Immunotherapy Congress is coming to the USA after an acclaimed launch in Europe. This inaugural event will bring together the brightest and best minds in pharma, biotech, government and academia to build on the development and commercialization of new immunotherapy treatments.. Co-located with the Americas Antibody Congress, Immunotherapy World Congress USA features 2 days of in-depth case studies and discussions around Cell Therapy Strategies, Pre-Clinical Development and Innovative Therapeutic Approaches presented by our partners from biopharma and academia.. Click here to register.. ...https://adcreview.com/events/world-immunotherapy-congress-usa-2017/
Step 11: Immunotherapy | Nicklaus Children's Hospital
Immunotherapy is like a vaccination against your allergies. Vaccine shots are to prevent infections; immunotherapy shots are to prevent allergies. However, the two work in opposite ways. Vaccinations prime the immune system to help the body react swiftly if the disease is encountered again, whereas immunotherapy dulls the reaction to allergens.. In the long term, allergy shots can minimize the need for antihistamines or other allergy medications. Immunotherapy builds up your tolerance to specific allergens, so your body won't overreact to them.. Immunotherapy shots are used for most airborne allergens, including tree, grass, and weed pollens, mold spores, dust mites, and animal allergens. Immunotherapy shots can also be used to prevent severe sting reactions from honeybees, yellow jackets, hornets, wasps, or fire ants. ...https://www.nicklauschildrens.org/care-guides/step-11-immunotherapy
Frontiers in Oncology 2017 August 24 [Link] Pease DF, Kratzke RA Abstract The limited effectiveness of conventional therapy for malignant pleural mesothelioma demands innovative approaches to this difficult disease. Even with aggressive multimodality treatment of surgery, radiation, and/or chemotherapy, the median survival is only 1-2 years depending on stage and histology. Oncolytic viral therapy has emerged […]. ...http://www.mesothelioma-line.com/category/type-of-assessment/treatment/immune-based-therapies/
HON - News : Immune-Based Therapy Shows Early Promise Against MS
THURSDAY, April 20, 2017 (HealthDay News) -- An experimental immune-system therapy appears safe for people with progressive forms of multiple sclerosis. And it may ease symptoms in some, a preliminary study suggests.. The findings are based on just six patients, and the Australian researchers stressed that a lot of work still lies ahead.. But they were encouraged that this new approach to MS had no major side effects. In addition, three of the six patients showed symptom improvements, including reduced fatigue and better mobility.. It's not clear, however, what to make of those improvements, said Bruce Bebo, executive vice president of research for the National Multiple Sclerosis Society.. The study was a "phase 1" trial, meaning it was designed only to test the therapy's safety.. "Based on this very preliminary study, the therapy appears safe," said Bebo, who was not involved in the research.. "But I'd be even more cautious in drawing any conclusions about the clinical improvements," he ...http://www.hon.ch/News/HSN/721885.html
Understanding Immunotherapy and Cancer Immunotherapy Archives »
Understanding Immunotherapy Immunotherapy is a broad category of anti-cancer therapies that use the body's immune system to fight cancer cells. These cells are different from normal cells, in that they do not die normally. What Is Cancer Immunotherapy Immunotherapy is treatment that uses certain parts of a person's immune system to fight. ...http://selectoday.com/tag/understanding-immunotherapy-and-cancer-immunotherapy/
2017 Forecast - cancer immunotherapies Global Market, Industry Size, Share, Analysis and Opportunities to 2023. | Market...
Before It's News). Latest industry research report on Antibody drug conjugates Market. Cancer Immunotherapy has brought an unprecedented change in the global cancer therapies market. Cancer immunotherapy can be defined as, the treatment that deploys the body's immune system, by joining and boosting innate powers of the immune system to fight cancer.. Over the past few years, cancer immunotherapies have generated new waves of optimism in the global oncology market, unveiling huge untapped potential for the innovators. After years of jostling over how to use the body's immune system against cancer, researchers are now spotting newer targets and mechanisms to overcome the loopholes of conventional therapies.. Get Free Sample Report Of Antibody drug conjugates Market @ http://www.marketresearchstore.com/report/world-cancer-immunotherapies-market-opportunities-and-forecasts-71696#RequestSample. On the back of properties such as, comparably long-lived effects, exquisite ...http://beforeitsnews.com/market-research-reports/2017/03/2017-forecast-cancer-immunotherapies-global-market-industry-size-share-analysis-and-opportunities-to-2023-258.html
Post-Doctoral Scientist, Sotomayor Lab
The George Washington University Cancer Center is a collaboration between the GW Hospital, the GW Medical Faculty Associates, the GW School of Medicine and Health Sciences, and the Milken Institute School of Public Health at GW to expand GW's efforts in the fight against cancer. The GW Cancer Center also incorporates all existing cancer-related activities at GW, serving as a platform for future cancer services and research development.. The Director of the GW Cancer Center, Dr. Eduardo Sotomayor, is an internationally recognized visionary in the field of lymphoma research and treatment. His primary area of research is immunobiology and immunotherapy of B-cell malignancies, with special emphasis on the design of novel immunotherapeutic approaches for these diseases. Clinically, Sotomayor has a particular interest in mantle cell lymphoma, an aggressive subtype of B-cell non-Hodgkin lymphoma. He has developed an extensive portfolio of basic, translational, and clinical research initiatives for ...https://www.gwu.jobs/postings/47893
Study suggests immunotherapy may help overcome trastuzumab-resistance in breast cancer - EPM Magazine
Results from the PANACEA study, recently presented at the San Antonio Breast Cancer Symposium, have suggested that immunotherapy may help to overcome trastuzumab-resistant breast cancer.https://www.epmmagazine.com/news/study-suggests-immunotherapy-may-help-overcome-trastuzumab-r/
Characterization of murine pancreatic carcinoma models regarding immunosuppressive mechanisms and therapy with bifunctional...
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive tumor that is characterized by abundant tumor stroma and a potent immunosuppressive microenvironment. Further studies to clarify why T cells infiltrate the tumor but are not able to perform effector functions as well as to find new effective therapies to overcome immunosuppression are urgently needed. The aims of the present study were (1) to characterize different murine PDAC tumor models in regard to their utility for studying novel immunotherapeutic approaches, (2) to assess the therapeutic efficacy of a novel bifunctional ppp-siRNA that combines silencing of the immunosuppressive molecule galectin-1 and RIG-I-mediated immune activation in murine PDAC and (3) to characterize the immunosuppressive mechanisms leading to T cell inhibition in the tumor microenvironment. (1) This study revealed that the pancreatic cancer cell line T110299, which was developed from a primary tumor of the KPC mouse model, is a new valuable tool for ...https://edoc.ub.uni-muenchen.de/17449/index.html
Cyclooxygenase-2 (COX2) gene silencing with siRNA could enhance DNA vaccination to inhibit established ErbB-2 carcinomas |...
Background: Cyclooxygenase-2 (COX2) is the key enzyme in the synthesis of prostaglandin E2 from its precursor, arachidonic acid. The level of COX2 is normally very low in cells but increased amounts of COX2 are commonly detected in both premalignant and malignant tissues. In order to investigate COX2 as a potential target for the prevention and treatment of cancer, we propose a novel immunotherapeutic approach for the prevention of ErbB-2 positive breast carcinomas, based on DNA vaccination against a specific antigen (ErbB-2) in combination with the silencing of COX2. Material and methods: The short hairpin RNA interference cassette targeting COX2 mRNA, containing the mouse RNA promoter U6, was amplified and cloned into the Eco72I site of pVAX-ratECTM (RRT), a vector carrying the extracellular and transmembrane domains of rat ErbB-2, and into pVAXI, to obtain respectively RRT-COX2 and pVAXCOX2. The gene silencing efficacy of both plasmids was checked by transfecting COX2 over-expressing A17 ...https://pubblicazioni.unicam.it/handle/11581/250358
Cancer Vaccines : Pharmaceuticals : UK
Stephanie McArdle is at the head of T-cell vaccine immunotherapy, which is mainly focused on the validation of novel immunotherapeutic targets as well as immune-phenotyping patient's blood. She is particularly interested in HAGE and PAP antigens as targets and/or biomarkers for cancers. She is also very interested in understanding the role of stress and diet supplement on vaccine outcome. Stephanie supervises many PhD students as director of studies as well as second supervisor and MSc/MRes students. She has recently successfully completed projects contracted by two companies. Academically she has attended the supervisor course as well as the Post-Graduate Certificate for Higher Education (PGCHE) course. Stephanie helps in the teaching of Immunology and Cancer subject areas and regularly reviews original and review type of papers for journals such as Cancer Immunotherapy, Vaccine, Immunology, European Journal of Cancer, Cancer Therapy, Amino-Acids, vaccine supplement and ...http://www.smi-online.co.uk/pharmaceuticals/uk/conference/cancer-vaccines
OSE Immunotherapeutics Signs a License Option Agreement with Inserm to Develop a New Cancer Immunotherapy Targeting Myeloid...
http://ose-immuno.com/site/wp-content/uploads/logo-OSE-immunotherapeutics.png 0 0 sylviedetry http://ose-immuno.com/site/wp-content/uploads/logo-OSE-immunotherapeutics.png sylviedetry2017-09-28 17:59:212017-09-28 17:59:21OSE Immunotherapeutics Signs a License Option Agreement with Inserm to Develop a New Cancer Immunotherapy Targeting Myeloid Cells ...http://ose-immuno.com/en/ose-immunotherapeutics-signs-a-license-option-agreement-with-inserm-to-develop-a-new-cancer-immunotherapy-targeting-myeloid-cells/
New Immunotherapy Approach to Treat Chronic Infections - Healthcanal.com : Healthcanal.com
Prof. Dr. Ulrike Protzer. With the discovery and development of vaccines, modern medicine succeeded in combating infectious pathogens. "The disadvantage, however, is that vaccinations must be prophylactic, that is they must take place before the first contact with the pathogen," said Professor Percy Knolle, who was previously director of the Institute of Molecular Medicine of the University of Bonn and is now director of the Institute of Molecular Immunology of TU München (TUM). Until now, post-infection protection by means of vaccination has not been possible for common chronic infections with hepatitis viruses. These infections can progress to chronic liver inflammation and cause organ damage, eventually leading to a dangerous liver cirrhosis or liver cancer. Scientists of the University of Bonn, together with their colleagues at TUM and Helmholtz Zentrum München as well as other national and international institutes, have now made a promising discovery in animal models. "We have discovered ...https://www.healthcanal.com/infections/37914-new-immunotherapy-approach-to-treat-chronic-infections.html
Immunotherapy - What's New in GU?
Immunotherapy, broadly defined as using the body's own immune system to fight cancer, is one of the most exciting developments in cancer care. In oncology, for some patients using an immunotherapy treatment approach has resulted in some deep and prolonged responses.. The field of genitourinary (GU) oncology one was of the first sub-specialty areas to utilize immunotherapy and compared to many other tumor types, GU oncology has been using it for the longest amount of time - particularly for kidney (renal) and bladder cancers. There have been more recent advances across the board in immunotherapy, including the approval of atezolizumab by the FDA for bladder and urothelial cancers, marking the first new treatment for that tumor type in nearly three decades. Additionally, in select patients who have advanced urothelial cancer that has not responded to platinum-based chemotherapy, adding immunotherapy with pembrolizumab to the ...https://weillcornellgucancer.org/category/immunotherapy/
Immunotherapy - What's New in GU?
Immunotherapy, broadly defined as using the body's own immune system to fight cancer, is one of the most exciting developments in cancer care. In oncology, for some patients using an immunotherapy treatment approach has resulted in some deep and prolonged responses.. The field of genitourinary (GU) oncology one was of the first sub-specialty areas to utilize immunotherapy and compared to many other tumor types, GU oncology has been using it for the longest amount of time - particularly for kidney (renal) and bladder cancers. There have been more recent advances across the board in immunotherapy, including the approval of atezolizumab by the FDA for bladder and urothelial cancers, marking the first new treatment for that tumor type in nearly three decades. Additionally, in select patients who have advanced urothelial cancer that has not responded to platinum-based chemotherapy, adding immunotherapy with pembrolizumab to the ...https://weillcornellgucancer.org/tag/immunotherapy/
Allergy Immunotherapies Sales Market Capacity, Production, Revenue, Price and Gross Margin, Analysis & Forecast by 2022 |...
Further in the Allergy Immunotherapies Sales Market Industry Analysis report, the Allergy Immunotherapies Sales Market is examined for price, cost and gross. These three points are analysed for types, companies and regions. In continuation with this data sale price is for various types, applications and region is also included. The Allergy Immunotherapies Sales Market for major regions is given. Additionally, type wise and application wise consumption figures are also given.. Scope of the Allergy Immunotherapies Sales Market on the basis of region:. • North America. • China. • Europe. • Japan. • India. • Southeast Asia. The Allergy Immunotherapies Sales Market analysis report also speaks about the manufacturing process. The process is analysed thoroughly with respect three points, viz. raw material and equipment suppliers, various manufacturing associated costs (material cost, labour cost, etc.) and the actual process.. No. of Report Pages: 113. Price of Report (Single User Licence): ...http://beforeitsnews.com/business/2017/02/allergy-immunotherapies-sales-market-capacity-production-revenue-price-and-gross-margin-analysis-forecast-by-2022-3178986.html